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if novel oral anticoagulants (NOAC) had comparable efﬁcacy and
safety to that of warfarin for AF ablation.
METHODS PubMed, Google Scholar and EBSCO were queried for
studies comparing NOACS and warfarin use for peri-procedural AF
ablation. Data on thromboembolic events (TE), major and minor
bleeding was then extracted from the included studies. Meta-analysis
was carried out using Mantel-Haenszel random effects risk ratio (RR)
model.
RESULTS A total of 26 studies with 11,298 patients were included in
this analysis. Warfarin and NOACS were used in 7496 and 3802 pa-
tients respectively. TE occurred in 0.42% and 0.29% of the NOAC and
Warfarin groups, respectively. The incidence of major bleeding was
similar and occurred in 1.2% in both groups. The risk of TE for the
NOAC group was 1.28 (95% CI 0.56 – 2.96, p¼0.56) compared to
warfarin. There were no subgroup differences with the use of Apix-
aban, Dabigatran or Rivaroxaban. The risk of major bleeding was also
similar between the two groups (RR 0.95, 95% CI 0.59 – 1.53, p¼0.82).
Minor bleeding occurred in 3.4% and 4.2% in the NOAC and warfarin
groups respectively. Subgroup exclusion sensitivity analyses of indi-
vidual drugs of apixaban, dabigatran and rivaroxaban did not alter the
above outcomes. The heterogeneity between the included studies was
extremely low (I2¼0%). Publication bias was assessed using funnel
plot and showed minimal bias.
CONCLUSIONS The results of our study suggest that uninterrupted
NOAC and warfarin use with intra-procedural heparin use for AF
ablation have low and similar risk for TE and major bleeding. However
the risk of minor bleeding is decreased by 27% in the NOAC group.
Further randomized studies are needed to determine the beneﬁt with
the use of NOACS.
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BACKGROUND To date, there are limited data regarding combination
antiplatelet regimen (dual; asprin plus clopidogrel versus triple;
aspirin plus clopidogrel plus cilostazol) following percutaneous
transluminal angioplasty (PTA) in patients (pts) with symptomatic
peripheral arterial disease (PAD).
METHODS We investigated the 475 consecutive PAD pts underwent
PTA from September 2004 to December 2013. One-year clinicaloutcomes of symptomatic PAD pts treated with dual antiplatelets
(DAP, n¼241) were compared with those of PAD pts with triple anti-
platelets (TAP, n¼234). Cilostazol was maintained at least more than 1
month following PTA.
RESULTS At baseline, there were no signiﬁcant differences in
clinical characteristics including age, gender, hypertension, dysli-
pidemia, cerebrovascular accident (CVA), coronary artery disease,
myocardial infarction, congestive heart failure between the two
groups except diabetes, chronic renal insufﬁciency (CRI), and
smoking; the DAP group had higher incidence in diabetes and CRI,
whereas the TAP group had higher incidence of smoking. The
distribution of clinical symptom was as follows; 1: Claudication was
19.5% in DAP and 38% in TAP (p¼0.402), 2: resting pain was 5.4%
in DAP and 22.6% in TAP (p<0.001), 3: Wound was 72.2% in DAP
and 53.0% in TAP (p<0.001). 4: Gangrenous change was 27.4% in
DAP and 20.1% in TAP (p¼0.062). There was a trend toward higher
incidence of repeat PTA primarily due to higher trend of target
extremity revascularization (TER) at 1 year in the TAP group. This
result probably translated into trend toward lower incidence of
target extremity surgery (TER), particularly below-the-ankle
amputation in the TAP group (Table). There was no signiﬁcant
difference in 1-year major clinical outcomes including total death,
cardiac death, acute myocardial infarction (AMI), percutaneous
coronary intervention (PCI), CVA, and major adverse
cerebrocardiovascular events (MACCEs) between the two groups
(Table).
CONCLUSIONS In our study, despite of similar incidence of individ-
ual and composite hard endpoints between the DAP and TAP regimen
following PTA, the use of TAP was associated with higher trend of
repeat PTA and subsequent lower incidence of amputation at 1 year.CATEGORIES CORONARY: Pharmacology/Pharmacotherapy
KEYWORDS Antiplatelet therapy, Peripheral arterial diseaseTCT-217
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BACKGROUND The effectiveness of dual antiplatelet therapy (DAPT)
for secondary prevention in speciﬁc patient’s subsets is unclear. We
sought to evaluate the effectiveness of longer durations of DAPT in
women and men.
METHODS We included gender-speciﬁc effect estimates from ran-
domized controlled trials (RCTs) testing DAPT in patients with CAD.
Study groups were classiﬁed as: shorter DAPT (S-DAPT), deﬁned as
B84 J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y , V O L . 6 6 , N O . 1 5 , S U P P L B , 2 0 1 5the per-protocol minimum duration of DAPT after the procedure,
and longer DAPT (L-DAPT) deﬁned as the per-protocol period of
prolonged DAPT beyond S-DAPT. The primary outcome was the
study-deﬁned major adverse cardiac events (MACE). Random effect
models were used as primary analytic approach with generic in-
verse variance using effect estimates and standard errors extracted
from each RCT’s gender subgroup analysis. Heterogeneity was
assessed with I2 test (with I2 > 75% indicating substantial hetero-
geneity). Analyses were conducted with Cochrane’s Review Man-
ager (RevMan) version 5.3.
RESULTS A total of 13 RCTs with 108.069 patients have been
included in the ﬁnal dataset. Of them, 31,390 (29%) were women
and 76,679 (71%) were men. Mean weighted exposure time to DAPT
was 2.4 months and 5.9 months in the S-DAPT and L-DAPT groups
respectively. Compared with S-DAPT, L-DAPT was associated with a
signiﬁcant reduction in MACE in the overall cohort (Figure. HR:
0.87; 95% CI: 0.82 – 0.92; p < 0.00001; I2 ¼ 18%). However, the
beneﬁt of L-DAPT was accentuated in men (HR: 0.82; 95% CI:
0.76 – 0.90; p < 0.00001) as compared to women (HR: 0.93; 95%
CI: 0.86 – 1.00; p ¼ 0.06) with evidence of statistical interaction
(p for interaction ¼ 0.03).CONCLUSIONS According to the results of the present study-level
metanalysis, the beneﬁts of DAPT appear to be less in women as
compared to men, a ﬁnding that warrants prospective conﬁrmation.
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BACKGROUND Longer DAPT (> 12 months) after drug-eluting stent
(DES) implantation is associated with a lower risk of myocardial
infarction (MI) counterbalanced by a higher risk of major bleeding
events. We sought to simulate the therapeutic risks and beneﬁts of
longer versus short DAPT durations after PCI using evidence from
randomized controlled trials (RCT).
METHODS Using frequentist meta-analytic techniques, we calculated
summary effect estimates for both MI and clinically signiﬁcant
bleeding (CSB) associated with longer (L-DAPT) versus shorter (S-
DAPT) DAPT durations based on results of 10 RCT (n¼32,135). We then
calculated the number needed to treat (NNT) and number needed toharm (NNH) as a function of baseline thrombotic and bleeding risk.
NNT/NNH ratios > 1 were considered as evidence of therapeutic harm
while ratios < 1 were classiﬁed as beneﬁcial.
RESULTS The mean weighted follow-up time among all trials was
19.6 months. Mean weighted exposure time to DAPT was 23.2
months and 8.5 months in L-DAPT and S-DAPT groups respectively.
As compared to S-DAPT, L-DAPT was associated with a lower risk of
MI (odds ratio [OR]: 0.72; 95% CI: 0.62 – 0.83; p < 0.0001).
Conversely, L-DAPT was associated with a higher risk of CSB (OR:
1.59; 95% CI: 1.31 – 1.92; p < 0.00001). The net clinical beneﬁt in the
trade-off between ST and CSB across a range of bleeding and
ischemic risk scenarios is illustrated in Figure 1. With L-DAPT, the
beneﬁt on MI outweighed the risk for bleeding with a ST risk > 6%
and a CSB risk  3%.
CONCLUSIONS Our results suggest that the beneﬁts of longer DAPT
durations may be optimal in patients at high thrombotic or low
bleeding risk, ﬁndings that warrant prospective evaluation.CATEGORIES CORONARY: Pharmacology/Pharmacotherapy
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BACKGROUND Randomized data have shown that prasugrel is supe-
rior to clopidogrel in reducing ischemic risk including unplanned
revascularization, albeit with increased bleeding. Greater stent length
is also an independent correlate of adverse events after percutaneous
coronary intervention (PCI). We sought to determine whether
